Cardiology / Cardiovascular
Cardiovascular guidance, trial updates, drug mechanisms and CPD resources for clinicians following rapidly changing prevention, heart failure and cardiometabolic evidence.
Latest Guidelines
Finerenone for treating chronic heart failure with preserved or mildly reduced ejection fraction
Finerenone is recommended as an option for chronic heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF) and can be initiated in primary or secondary…
Aficamten for treating symptomatic obstructive hypertrophic cardiomyopathy
Patient selection: Consider aficamten for symptomatic obstructive hypertrophic cardiomyopathy patients who remain symptomatic despite optimised standard therapy (beta-blockers, non-dihydropyridine calcium channel blockers, or disopyramide), or who…
Netarsudil for treating open-angle glaucoma or ocular hypertension (terminated evaluation)
Netarsudil evaluation by NICE was terminated, indicating it is not recommended for routine use in NHS treatment pathways for open-angle glaucoma or ocular hypertension—continue using established…
Sotatercept for treating pulmonary arterial hypertension
Sotatercept is recommended as a treatment option for pulmonary arterial hypertension (PAH) in patients who meet NICE criteria; verify patient eligibility and existing PAH therapy status…
Artificial intelligence (AI)-assisted echocardiography analysis and reporting to support the diagnosis and monitoring of heart failure: early-use assessment
AI-assisted echocardiography can support faster preliminary analysis and reporting of echo images in heart failure patients, potentially reducing reporting delays and improving clinical workflow efficiency in…
Semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity
Semaglutide is recommended for adults with established cardiovascular disease and overweight/obesity to reduce major adverse cardiovascular events – consider prescribing as part of a comprehensive cardiovascular…
Trial Radar
Efficacy and Safety of a Nitric Oxide Generating Dressing for Diabetic Foot Ulcers (ONWARD)
Real world evidence study on the performance and safety of a nitric oxide generating dressing on the treatment…
PHASE3A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-004)
What is being tested: MK-8748, a novel investigational therapy, is being compared against aflibercept (standard treatment) to evaluate…
PHASE3Study of ALXN2220 Versus Placebo in Adults With ATTR-CM
ALXN2220 drug tested against placebo in adults with heart amyloidosis, measuring death and heart-related events.
PHASE3A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).
Treatment Being Tested: AZD0120 (a novel consolidation therapy) is being compared against autologous stem cell transplantation (ASCT) as…
Clinical News
Inside Health
Key Takeaways for Clinical Practice Stroke incidence is rising disproportionately in Black communities – clinicians should be alert…
13 Oct 2026‘I was dead for 10 minutes, but lived to tell the tale’
Cardiac arrest survival is possible with rapid intervention: A patient in Spain survived 10 minutes of cardiac arrest,…
10 Oct 2026Dad thankful charity scan revealed ‘silent’ heart attack
Asymptomatic coronary artery disease can be clinically significant—charity screening identified a blocked artery in a patient without symptoms,…
30 Sep 2026The children dying in India’s remote tribal heartland
Measles and malaria resurgence in vulnerable populations: At least 32 child deaths in Balaghat district highlight ongoing risks…
Relevant Mechanisms
Coagulation Factor Xa/IIa — DOACs
Coagulation Factor Xa/IIa — DOACs is a clinically relevant Drug Science explainer. The coagulation cascade proceeds via two convergent pathways…
MechanismGLP-1 Receptor Agonism
GLP-1 Receptor Agonism is a clinically relevant Drug Science explainer. Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from intestinal…
MechanismHMG-CoA Reductase — Statins
HMG-CoA Reductase — Statins is a clinically relevant Drug Science explainer. 3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase catalyses the rate-limiting step…
MechanismPCSK9 Inhibition
PCSK9 Inhibition is a clinically relevant Drug Science explainer. PCSK9 (proprotein convertase subtilisin/kexin type 9) is a serine protease secreted…
MechanismRAAS Pathway
RAAS Pathway is a clinically relevant Drug Science explainer. The renin-angiotensin-aldosterone system (RAAS) is a hormonal cascade governing blood pressure,…
CPD, Podcasts & Webinars
Follow Cardiology / Cardiovascular safety updates
Get MHRA safety alerts and clinically relevant updates for this specialty in your ClinicaliQ digest.
Follow Cardiology / Cardiovascular
Choose guideline, trial, Drug Science and education updates for this specialty.